PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452
PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiology’s 68th Annual Scientific Session
Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, have been selected for oral presentation during a featured clinical research session at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19), being held March 16-18, 2019, at the Ernest N. Morial Convention Center in New Orleans.
Title: First Randomized Human Experience with a Ticagrelor Reversal Agent
Session: Late-Breaking Clinical Trials, Featured Clinical Research II: Interventional
Session Number: 408
Date / Time: Sunday, March 17, 2-2:10 p.m. CDT
Location: Ernest N. Morial Convention Center, Room 206
Presenter: Deepak L. Bhatt, M.D., M.P.H.; Brigham and Women’s Hospital and Harvard Medical School
Additional information on the scientific session can be found on the ACC website: https://accscientificsession.acc.org/.
[Originally posted by PHASE Bio — March 4, 2019]